Wolfe Research initiated coverage on Celcuity with a new price target
$CELC
Medical Specialities
Health Care
Wolfe Research initiated coverage of Celcuity with a rating of Outperform and set a new price target of $110.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | $126.00 | Overweight | Wells Fargo |
| 11/18/2025 | $110.00 | Outperform | Wolfe Research |
| 11/17/2025 | Buy → Neutral | H.C. Wainwright | |
| 9/22/2025 | $110.00 | Buy | Guggenheim |
| 7/1/2025 | $30.00 | Buy | Stifel |
| 7/22/2024 | $29.00 | Outperform | Leerink Partners |
| 2/22/2024 | $40.00 | Buy | Stifel |
| 12/8/2023 | $27.00 | Buy | H.C. Wainwright |
4 - Celcuity Inc. (0001603454) (Issuer)
The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type ("WT") advanced breast cancer ("ABC")Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical OncologyTopline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDT MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcu
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed usi
As previously presented, gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and gedatolisib + fulvestrant ("gedatolisib doublet") reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormon
8-K - Celcuity Inc. (0001603454) (Filer)
SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
SCHEDULE 13G/A - Celcuity Inc. (0001603454) (Subject)
Wells Fargo initiated coverage of Celcuity with a rating of Overweight and set a new price target of $126.00
Wolfe Research initiated coverage of Celcuity with a rating of Outperform and set a new price target of $110.00
H.C. Wainwright downgraded Celcuity from Buy to Neutral
4 - Celcuity Inc. (0001603454) (Issuer)
3 - Celcuity Inc. (0001603454) (Issuer)
4 - Celcuity Inc. (0001603454) (Issuer)
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. "Chip brings a wealth of oncology-related commercial expertise to our Board," said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. "Chip's deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G/A - Celcuity Inc. (0001603454) (Subject)
SC 13G - Celcuity Inc. (0001603454) (Subject)
The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type ("WT") advanced breast cancer ("ABC")Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical OncologyTopline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDT MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcu
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed usi
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webli